Release date: 2025-03-10 10:36:16 Article From: Lucius Laos Recommended: 80
The development of cancer treatment drugs has brought hope to patients, but it has also been accompanied by concerns about the side effects of drugs. This article will discuss the use of osimertinib, a lung cancer treatment, and its possible side effects.
In the treatment of lung cancer, osimertinib has been widely recognized as the first-line standard of care for patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. However, any drug has the potential to bring side effects, and osimertinib is no exception.
According to clinical data, one of the most common adverse reactions of osimertinib is diarrhea, which was reported in about 31.4% of patients. In addition to this, skin problems and paronychia may also experience side effects associated with EGFR inhibitors. These side effects, while not always severe, do affect the quality of life of a subset of patients.
In addition to side effects, another concern for osimertinib is its resistance. Approximately 43.8% of patients developed brain or meningeal metastases after treatment with osimertinib. This means that over time, some patients may find that the drug is less effective and need to consider other treatment options.
For those who experience osimertinib resistance, doctors often recommend anti-angiogenic drugs as part of subsequent treatment. In addition, specific genetic variants, such as the C797S mutation, may require a more individualized treatment strategy.
As medical research advances, scientists are looking for more effective treatments with fewer side effects to fight cancer.
To overcome the limitations of existing drugs, researchers are working on the development of novel targeted drugs. For example, fruquintinib was included in the NCCN guidelines for its high-level evidence-based evidence, marking a substantial advance in the treatment of colorectal cancer. These new drugs not only improve the efficacy, but also have the potential to reduce the strong side effects of traditional chemotherapy.
Personalized medicine has become an important trend in oncology. Through genetic testing and other diagnostic tools, doctors are able to better understand the characteristics of each patient's disease and develop a treatment plan that works best for them. This includes choosing the most appropriate combination of medications as well as adjusting the dosage to achieve the best results while minimizing side effects.
Despite significant advances in targeted therapy, monotherapy is often difficult to cure complex diseases. A comprehensive treatment strategy that combines surgery, radiotherapy, chemotherapy and other means is particularly important. Such multidisciplinary collaboration can help improve patient survival and improve quality of life.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: